Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kudingxiang Tongqi (苦丁香通气栓) is a rectal suppository formulation used in China, primarily for the management of postoperative intestinal paralysis (also known as paralytic ileus). It is administered rectally, typically at a dose of 1.2 grams per suppository, with two doses given after surgery—one at 12 hours and another at 24 hours post-operation. The product is based on traditional Chinese medicine principles and contains herbal ingredients such as Kuding (Ilex kudingcha) and Dingxiang (clove), which are believed to promote gastrointestinal motility, relieve abdominal distension, and facilitate the recovery of bowel function following abdominal surgery. Its mechanism involves promoting Qi circulation and resolving stagnation according to TCM theory; however, specific molecular targets are not well characterized in Western pharmacology[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kudingxiang tongqi.